Improving global access to palliative care and pain relief

Editor’s Choice for October 2018

Comment on 'Ovarian Cancer: An ESMO Guide for Patients'

The IMpower-132 trial for non small cell lung cancer

ILLUMINATE 301: ipilimumab versus IMO-2125 combined with ipilimumab in anti PD 1 refractory melanoma

Keynote lecture: Mutation signatures and targeting the DNA damage response

Dosing regiment in the combination of ipilimumab and nivolumab in stage III melanoma

COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma

Modern melanoma treatment in the UK

Current clinical landscape for ALK non-small cell lung cancer patients

Latest advances in treatment for ALK positive NSCLC

The case for biosimilars